Global framework for biosimilars "is now crucial" Pharma Times Given the upcoming patient expiries on a number of major biologic drugs, including Roche's Herceptin (trastuzumab) and Rituxan (rituximab), Sanofi's Lantus Insulin glargine) and Amgen's Neulasta (pegfilgrastim), the move "cannot have come at a more ... |
